Skip to main content

Table 3 Intra-ICU and post-ICU outcome data in our study regarding the prevalence of ICU infections [due to either ABRP (N = 58) or non-ABRP (N = 57)] or not (N = 236)

From: The role of antimicrobial resistance on long-term mortality and quality of life in critically ill patients: a prospective longitudinal 2-year study

 

ABRP infections

Non-ARP infections

No infections

P-value

Population overall (N = 351)

N = 58

N = 57

N = 236

 

Intra-ICU outcomes

Critical Illness Myopathy

22 (37.9)

11 (19.3)

9 (3.8)

 < 0.001

Tracheostomy on discharge

19 (15.5)

11 (19.3)

8 (3.4)

 < 0.001

Length of stay, days

29.6 ± 21.1

16.6 ± 13.6

6.6 ± 7.7

 < 0.001a,b,c

MV days

23.3 ± 17.6

13.1 ± 10.8

4.6 ± 6.7

 < 0.001a,b,c

ICU cost/patient, euros

13,515 ± 7761

8330 ± 5698

4183 ± 3877

 < 0.001a,b,c

Intra-ICU mortality

24 (41.4)

18 (31.6)

56 (23.7)

0.022

Post-ICU outcomes

90-day mortality

42 (72.4)

33 (57.9)

109 (46.2)

0.001

2-year mortality

46 (79.3)

37 (64.9)

133 (56.36)

0.005

0.5-year QALYs

0.041 ± 0.085

0.073 ± 0.106

0.057 ± 0.097

0.077

1-year QALYs

0.105 ± 0.219

0.180 ± 0.265

0.142 ± 0.245

0.098

1.5-year QALYs

0.167 ± 0.358

0.289 ± 0.433

0.228 ± 0.4

0.101

2-year QALYs

0.228 ± 0.501

0.399 ± 0.604

0.313 ± 0.559

0.101

ICU survivors (N = 253)

N = 34

N = 39

N = 180

 

90-day mortality

18 (52.9)

15 (38.5)

53 (29.4)

0.024

2-year mortality

22 (64.7)

19 (48.7)

103 (57.2)

0.061

0.5-year QALYs

0.070 ± 0.102

0.107 ± 0.113

0.159 ± 0.142

0.001b

1-year QALYs

0.179 ± 0.263

0.264 ± 0.285

0.380 ± 0.341

0.002 b

1.5-year QALYs

0.285 ± 0.432

0.423 ± 0.468

0.594 ± 0.543

0.003 b

2-year QALYs

0.389 ± 0.608

0.584 ± 0.654

0.808 ± 0.747

0.004 b

  1. Continuous data are presented as means ± SD, categorical data as n (%)
  2. ICU intensive care unit, ABRP antibiotic resistant pathogen, MV days days on mechanical ventilation, QALY quality-adjusted life years
  3. aP < 0.05, ABRP versus non-ABRP group
  4. bP < 0.05, ABRP versus no-infection group
  5. cP < 0.05, non-ABRP versus no-infection group (Bonferroni’s post hoc analysis)